'%3e%3cpath%20d='M29.5529%2025.4577C28.9763%2024.0918%2028.1395%2022.8511%2027.0891%2021.8047C26.0419%2020.7553%2024.8014%2019.9186%2023.4361%2019.3408C23.4239%2019.3347%2023.4116%2019.3317%2023.3994%2019.3256C25.3039%2017.95%2026.5419%2015.7092%2026.5419%2013.1812C26.5419%208.99325%2023.1487%205.6001%2018.9608%205.6001C14.7729%205.6001%2011.3797%208.99325%2011.3797%2013.1812C11.3797%2015.7092%2012.6177%2017.95%2014.5222%2019.3286C14.51%2019.3347%2014.4977%2019.3378%2014.4855%2019.3439C13.116%2019.9216%2011.8871%2020.7501%2010.8325%2021.8078C9.78311%2022.8549%208.94642%2024.0954%208.36866%2025.4607C7.80106%2026.7974%207.49494%2028.2304%207.46687%2029.6823C7.46606%2029.7149%207.47178%2029.7474%207.4837%2029.7778C7.49563%2029.8082%207.51351%2029.8358%207.5363%2029.8592C7.55909%2029.8826%207.58633%2029.9011%207.6164%2029.9138C7.64648%2029.9265%207.67879%2029.933%207.71142%2029.933H9.54556C9.68007%2029.933%209.78706%2029.826%209.79011%2029.6945C9.85125%2027.3346%2010.7989%2025.1245%2012.4741%2023.4493C14.2073%2021.716%2016.5092%2020.7623%2018.9608%2020.7623C21.4124%2020.7623%2023.7143%2021.716%2025.4475%2023.4493C27.1227%2025.1245%2028.0703%2027.3346%2028.1315%2029.6945C28.1345%2029.829%2028.2415%2029.933%2028.376%2029.933H30.2102C30.2428%2029.933%2030.2751%2029.9265%2030.3052%2029.9138C30.3353%2029.9011%2030.3625%2029.8826%2030.3853%2029.8592C30.4081%2029.8358%2030.426%2029.8082%2030.4379%2029.7778C30.4498%2029.7474%2030.4555%2029.7149%2030.4547%2029.6823C30.4242%2028.2211%2030.1215%2026.7997%2029.5529%2025.4577ZM18.9608%2018.4391C17.5577%2018.4391%2016.2371%2017.8919%2015.2436%2016.8984C14.2501%2015.9049%2013.7029%2014.5843%2013.7029%2013.1812C13.7029%2011.7781%2014.2501%2010.4575%2015.2436%209.46401C16.2371%208.47052%2017.5577%207.92334%2018.9608%207.92334C20.3639%207.92334%2021.6845%208.47052%2022.678%209.46401C23.6715%2010.4575%2024.2187%2011.7781%2024.2187%2013.1812C24.2187%2014.5843%2023.6715%2015.9049%2022.678%2016.8984C21.6845%2017.8919%2020.3639%2018.4391%2018.9608%2018.4391Z'%20fill='white'/%3e%3c/g%3e%3c/svg%3e)
Prof. Dr. Gheorghe-Andrei Dan
Carol Davila University of Medicine and Pharmacy Bucharest - Faculty of Medicine, Bucharest, Romania
+1
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
35Years (1992-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications25 August 2023 in European Heart Journal
Journal Article
RBRobert A Byrne
Robert A ByrneXRXavier Rossello
Xavier Rossello
JCJ J Coughlan
J J CoughlanEBEmanuele Barbato
Emanuele BarbatoCBColin Berry
Colin BerryEGESC Scientific Document Group
ESC Scientific Document Group
+21
22 September 2023 in European Heart Journal: Acute Cardiovascular Care
Journal Article
RBRobert A Byrne
Robert A ByrneXRXavier Rossello
Xavier RosselloJCJ J Coughlan
J J CoughlanEBEmanuele Barbato
Emanuele BarbatoCBColin Berry
Colin BerryKZKatja Zeppenfeld
Katja Zeppenfeld
+134
22 June 2023 in EP Europace
Journal Article
TTTobias Toennis
Tobias ToennisEBEmanuele Bertaglia
Emanuele Bertaglia
Axel Brandes
Wolfgang DichtlNFNina Fluschnik
Nina Fluschnik
PKPaulus Kirchhof
Paulus Kirchhof +12
Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate episodes occur in 10–30% of elderly patients without atrial fibrillation. However, it remains unclear whether the presence of these arrhythmias has therapeutic consequences. The presence of AHRE increases the risk of stroke compared with patients without AHRE. Oral anticoagulation would have the potential to reduce the risk of stroke in patients with AHRE but is also associated with a rate of major bleeding of ∼2%/year. The stroke rate in patients with AHRE appears to be lower than the stroke rate in patients with atrial fibrillation. Wearables like smart-watches will increase the absolute number of patients in whom atrial arrhythmias are detected. It remains unclear whether anticoagulation is effective and, equally important, safe in patients with AHRE. Two randomized clinical trials, NOAH-AFNET6 and ARTESiA, are expected to report soon. They will provide much-needed information on the efficacy and safety of oral anticoagulation in patients with AHRE.
1 September 2012 in American Heart Journal
Journal Article
RMRobert J. Mentz
Robert J. MentzJKJuan-Carlos Kaski
Juan-Carlos Kaski
GDGheorghe-Andrei Dan
Gheorghe-Andrei DanSGSidney Goldstein
Sidney Goldstein
NSNorman Stockbridge
Norman Stockbridge
COChristopher M. O'COnnor
Christopher M. O'COnnor
+6
25 September 2023 in European Journal of Internal Medicine
Journal Article
Giuseppe BorianiNBNiccolo’ Bonini
Niccolo’ BoniniMVMarco Vitolo
Marco Vitolo
DMDavide A Mei
Davide A Mei
Jacopo Francesco Imberti
Gregory Lip +7
13 September 2024 in EP Europace
Journal Article
BGBulent Gorenek
Bulent GorenekAWAdrianus P Wijnmaalen
Adrianus P Wijnmaalen
Andreas GoetteGMGurbet Ozge Mert
Gurbet Ozge Mert
BPBradley Porter
Bradley Porter
OCOvidiu Chioncel
Ovidiu Chioncel +7
Patients presenting with or alerting emergency networks due to acute heart failure (AHF) form a diverse group with a plethora of symptoms, risks, comorbidities, and aetiologies. During AHF, there is an increased risk of destabilizing the functional substrate and modulatory adding to the risk of ventricular arrhythmias (VAs) already created by the structural substrate. New VAs during AHF have previously identified patients with higher intra-hospital and 60-day morbidity and mortality. Risk stratification and criteria/best time point for coronary intervention and implantable cardioverter defibrillator implantation, however, are still controversial topics in this difficult clinical setting. The characteristics and logistics of pre-hospital emergency medicine, as well as the density of centres capable of treating AHF and VAs, differ massively throughout Europe. Scientific guidelines provide clear recommendations for the management of arrhythmias in patients with chronic heart failure. However, the incidence, significance, and management of arrhythmias in patients with AHF have been less studied. This consensus paper aimed to address the identification and treatment of VAs that complicate the course of patients who have AHF, including cardiogenic shock.
About Me
Gheorghe-Andrei Dan graduated from the Carol Davila University of Medicine and Pharmacy and is specialized in Internal Medicine and Cardiology. From 1993 to 1995, he subspecialized in Electrophysiology and Interventional Arrhythmology at Université Catholique de Louvain-Cliniques Universitaires de Mont-Godinne in Belgium, and his Ph.D. thesis was on interventional electrophysiology. He is currently an Emeritus Full Professor of Cardiology at the Carol Davila University of Medicine and Pharmacy and a first-degree researcher and senior consultant in cardiology and internal medicine. Dr. Dan is an Honorary Member of the Romanian Academy of Scientists. He is an Emeritus Fellow of the European Society of Cardiology, the American Heart Association, and the European Heart Rhythm Association, and a Fellow of the American College of Cardiology. He is a Golden Professional Member of the American Heart Association, President of the "N.G. Lupu" Internal Medicine Foundation, and Past President of the International Society of Cardiovascular Pharmacotherapy. He is also the Chief Editor of the Romanian Journal of Internal Medicine and the Deputy Editor of the Europace and The American Journal of Therapeutics. His passion for cardiology and electrophysiology and arrhythmias has translated into 237 publications, including valuable original research, authorship in 10 European guidelines, and contributions in 24 books.